Home Cart Sign in  
Chemical Structure| 1039455-84-9 Chemical Structure| 1039455-84-9

Structure of COTI-2
CAS No.: 1039455-84-9

Chemical Structure| 1039455-84-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

COTI-2 is an orally available thiosemicarbazone and mutant p53 activator with potential antineoplastic activity.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of COTI-2

CAS No. :1039455-84-9
Formula : C19H22N6S
M.W : 366.48
SMILES Code : S=C(N1CCN(C2=NC=CC=C2)CC1)N/N=C3CCCC4=C\3N=CC=C4
MDL No. :MFCD28502211

Safety of COTI-2

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Description
COTI-2, distinguished as a low-toxicity anticancer agent, is an orally bioavailable third-generation p53 activator that can reactivate mutant forms of p53 and concurrently inhibit the PI3K/AKT/mTOR signaling pathway. It has been shown to trigger apoptosis across various human tumor cell lines and possesses antitumor properties in head and neck squamous cell carcinoma (HNSCC) through both p53-dependent and independent mechanisms, effectively restoring mutant p53 to a wild-type structure[1].[2].[3].

In Vitro:

Cell Line
Concentration Treated Time Description References
human tumor primary culture 3-D explants 19-317 μM 72 h measure drug-induced cell death by delayed-loss-of-membrane integrity and ATP content Genes (Basel). 2023 Mar 19;14(3):747
T24 cells 0.5 and 1 μM 24, 48, 72, and 96 hr To evaluate the inhibitory effect of COTI-2 on the proliferation of bladder cancer cells, results showed that COTI-2 significantly inhibited the proliferation of T24 cells. Iran J Basic Med Sci. 2025;28(3):240-246
5637 cells 0.5 and 1 μM 24, 48, 72, and 96 hr To evaluate the inhibitory effect of COTI-2 on the proliferation of bladder cancer cells, results showed that COTI-2 significantly inhibited the proliferation of 5637 cells. Iran J Basic Med Sci. 2025;28(3):240-246
GLC-4/adr 0.48 μM 72 h Evaluate the anticancer activity of COTI-2 on GLC-4/adr cells, showing an IC50 of 0.48 μM, exhibiting 17.3-fold resistance J Med Chem. 2020 Nov 25;63(22):13719-13732
GLC-4 0.03 μM 72 h Evaluate the anticancer activity of COTI-2 on GLC-4 cells, showing an IC50 of 0.03 μM J Med Chem. 2020 Nov 25;63(22):13719-13732
SW480/Coti 9.51 μM 72 h Evaluate the anticancer activity of COTI-2 on SW480/Coti cells, showing an IC50 of 9.51 μM, exhibiting 18.9-fold resistance J Med Chem. 2020 Nov 25;63(22):13719-13732
SW480 0.56 μM 72 h Evaluate the anticancer activity of COTI-2 on SW480 cells, showing an IC50 of 0.56 μM J Med Chem. 2020 Nov 25;63(22):13719-13732
PCI13-wtp53 1.0 μmol/L 48 h To assess the effect of COTI-2 on gene expression through RNA sequencing analysis, results showed that COTI-2 restored the DNA binding properties and transcriptional activity of the p53 mutant protein. Clin Cancer Res. 2019 Sep 15;25(18):5650-5662
PCI13-G245D (mutant p53) 1.0 μmol/L 16 and 48 h To evaluate the effect of COTI-2 on DNA damage response and replication stress markers, results showed that COTI-2 increased phosphorylation levels of γH2AX (S139) and Chk1 (S345), inducing apoptosis. Clin Cancer Res. 2019 Sep 15;25(18):5650-5662
PCI13-pBabe (p53 null) 1.0 μmol/L 16 and 48 h To evaluate the effect of COTI-2 on DNA damage response and replication stress markers, results showed that COTI-2 increased phosphorylation levels of γH2AX (S139) and Chk1 (S345), inducing apoptosis. Clin Cancer Res. 2019 Sep 15;25(18):5650-5662

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Athymic nude mice AN3-CA human endometrial tumor xenografts Intravenously (i.v.) 25 mg/kg COTI-2 3 times a week, paclitaxel for 5 consecutive days, until study end Evaluate the combined therapeutic effect of COTI-2 with paclitaxel, results showed the combination was more effective than monotherapy with no overt toxicity PLoS One. 2018 Jan 24;13(1):e0191766
BALB/c nude mice T24 cell xenograft model Intraperitoneal injection 3 mg/kg Every other day for a total of eight injections To evaluate the inhibitory effect of COTI-2 on bladder cancer growth in vivo, results showed that COTI-2 significantly inhibited tumor growth and induced apoptosis. Iran J Basic Med Sci. 2025;28(3):240-246
Nude mice Orthotopic mouse model of oral tongue cancer Oral 75 mg/kg To evaluate the antitumor effects of COTI-2 alone and in combination with cisplatin or radiation, results showed that COTI-2 significantly inhibited tumor growth and enhanced sensitivity to cisplatin and radiation. Clin Cancer Res. 2019 Sep 15;25(18):5650-5662

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02433626 Ovarian Cancer ... More >> Fallopian Tube Cancer Endometrial Cancer Cervical Cancer Peritoneal Cancer Head and Neck Cancer HNSCC Less << Phase 1 Recruiting December 2018 United States, Illinois ... More >> Northwestern Memorial Hospital Recruiting Chicago, Illinois, United States Contact: Wilberto Nieves-Neira, MD    312-472-4684       Principal Investigator: Wilberto Nieves-Neira, MD          United States, Texas MD Anderson Cancer Centre Recruiting Houston, Texas, United States Contact: Shannon Westin, MD    713-794-4314       Principal Investigator: Shannon Westin, MD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.73mL

0.55mL

0.27mL

13.64mL

2.73mL

1.36mL

27.29mL

5.46mL

2.73mL

References

 

Historical Records

Categories